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Victoria M. Fiesler3, Jingfang Zhang4, Huachen Huang3, Md Nabiul Hasan3, Anna E. Skrzypiec1, Mariusz Mucha1,
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The SLC12A cation-Cl− cotransporters (CCC), including NKCC1 and the KCCs, are important
determinants of brain ionic homeostasis. SPAK kinase (STK39) is the CCC master regulator,
which stimulates NKCC1 ionic influx and inhibits KCC-mediated efflux via phosphorylation at
conserved, shared motifs. Upregulation of SPAK-dependent CCC phosphorylation has been
implicated in several neurological diseases. Using a scaffold-hybrid strategy, we develop a
novel potent and selective SPAK inhibitor, 5-chloro-N-(5-chloro-4-((4-chlorophenyl)(cyano)
methyl)-2-methylphenyl)-2-hydroxybenzamide (“ZT-1a”). ZT-1a inhibits NKCC1 and stimu-
lates KCCs by decreasing their SPAK-dependent phosphorylation. Intracerebroventricular
delivery of ZT-1a decreases inflammation-induced CCC phosphorylation in the choroid plexus
and reduces cerebrospinal fluid (CSF) hypersecretion in a model of post-hemorrhagic
hydrocephalus. Systemically administered ZT-1a reduces ischemia-induced CCC phosphor-
ylation, attenuates cerebral edema, protects against brain damage, and improves outcomes in
a model of stroke. These results suggest ZT-1a or related compounds may be effective CCC
modulators with therapeutic potential for brain disorders associated with impaired ionic
homeostasis.
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Regulation of cellular ion transport is critical for brain waterhomeostasis. Vectorial ion transport across apical andbasolateral membranes of the choroid plexus epithelium
(CPe), accompanied by transport of water, cotransported1–3 or
osmotically obligated4–7, results in daily cerebrospinal fluid (CSF)
secretion of >500 cc/day into brain ventricular spaces. Impaired
ionic homeostasis in CPe can result in hydrocephalus (accumu-
lation of excess CSF in the brain ventricles), as in the settings of
intraventricular hemorrhage (IVH) and infection1–3. Coordinated
transmembrane influx and efflux of ions and water is also
necessary for cell volume homeostasis in neurons, glia, and
blood–brain barrier (BBB) endothelial cells. Impaired cell volume
regulation following ischemic stroke and other brain injuries can
lead to cytotoxic cell swelling, disruption of BBB integrity, and
cerebral edema8–10. Hydrocephalus requires neurosurgical treat-
ment by permanent, catheter-based CSF shunting, whereas
treatment of ischemic stroke may require decompressive hemi-
craniectomy11. Both of these often morbid procedures have been
used for decades with minimal innovation12–14. Recent advances
in vascular stroke therapy such as clot lysis by recombinant tissue
plasminogen activator (rtPA) and clot removal by radiologically
guided thrombectomy are appropriate for fewer than 8% of
ischemic stroke patients15,16. Thus, development of novel phar-
macological modulators of brain ion transport is warranted to
provide nonsurgical alternatives to current morbid treatments of
these neurological disorders with altered volume homeostasis.
The electroneutral cation–Cl− cotransporters (CCCs) are
secondary-active plasmalemmal ion transporters that utilize elec-
trochemically favorable transmembrane gradients of Na+ and/or
K+, established by the ouabain-sensitive Na+, K+-ATPase to drive
transport of Cl− (and Na+/K+) into or out of cells. In epithelial
cells under most physiological conditions (with the possible
exception of choroid plexus), the Na+-driven CCCs NCC, NKCC1,
and NKCC2 (“N(KCCs”)17–22, function as Cl− importers, whereas
the Na+-independent KCC1–4 (“KCCs”)23–26 function as Cl−
exporters. These evolutionarily conserved transporters27 are of
particular importance in regulation of ion and water homeostasis in
mammalian central nervous system (CNS)28,29. The coordinated
regulation of CCC function is important for cell volume regulation
in most brain cells, preventing excessive cell swelling or shrinkage
in response to osmotic or ischemic stress26,30–34. The central
importance of CCCs to choroid plexus regulation of CSF home-
ostasis has been recently recognized1,3.
The Ste20-type Ser–Thr protein kinases SPAK (SPS1-related
proline/alanine-rich kinase) and OSR1 (oxidative stress-
responsive kinase 1) are considered master regulators of the
CCCs35. SPAK and OSR1 are activated by phosphorylation in the
regulatory “T-loop” (SPAK Thr233 and OSR1 Thr185) by one of
four WNK [“with no lysine” (K)] protein kinases17,36. The WNK
and SPAK/OSR1 protein kinases drive Cl− influx by phosphor-
ylation and activation of the Na+-driven CCC members (NCC,
NKCC1, and NKCC2)18–20 while inhibiting Cl− efflux by phos-
phorylation and inactivation of KCC1–425,26. This reciprocal
regulation of the Na+- and K+-driven CCCs by WNK–SPAK/
OSR1 ensures tight coordination of cellular Cl− influx and
efflux23,37, and is essential for regulation of cell volume and
epithelial transport in multiple tissues38.
SPAK-regulated, CCC-mediated ion transport has been
implicated in the pathogenesis of multiple brain pathologies
associated with impaired brain ion and water homeostasis.
Experimental ischemic cerebral edema is associated with
increased phosphorylation of the SPAK/OSR1 T-loop and of
NKCC1 (Thr203/Thr207/Thr212) in both neurons and oligo-
dendrocytes39, and in BBB endothelial cells40,41. Mouse germ-
line SPAK knockout significantly reduces ischemia-induced
NKCC1 phosphorylation, infarct volume, axonal
demyelination, and cerebral edema following ischemic
stroke39,42. Choroid plexus NKCC1 is an essential mediator of
ion transport in the CSF hypersecretory response that drives
development of post-hemorrhagic hydrocephalus3. The 3.5-fold
increase in CSF secretion accompanying the hydrocephalus
caused by experimental IVH is associated with upregulated
phosphorylation of SPAK/OSR1–NKCC1 at the choroid plexus
apical membrane3. Indeed, the choroid plexus is the site of the
highest SPAK abundance among all epithelial tissues22.
Knockdown of SPAK in the choroid plexus by intracer-
ebroventricular siRNAs reduced CSF secretion rates and
reversed post-IVH ventriculomegaly3.
Here, we report our development of a “dual” CCC modulator
(NKCC1 inhibitor/KCC activator), 5-chloro-N-(5-chloro-4-
((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)-2-hydro-
xybenzamide (“ZT-1a”) that potently and selectively inhibits
SPAK kinase. ZT-1a-mediated SPAK inhibition led to reduced
cellular ion influx and to stimulated Cl−-dependent K+ efflux by
simultaneous reduction of the activating phosphorylation of
NKCC1 and the inhibitory phosphorylation of the KCCs. Intra-
cerebroventricular delivery of ZT-1a prevented CSF hypersecre-
tion in a model of post-hemorrhagic hydrocephalus by decreasing
SPAK-mediated phosphorylation of CCCs in the choroid plexus.
Systemic ZT-1a administration after experimental ischemic stroke
attenuated cerebral infarction and edema and improved neuro-
logical outcomes by decreasing SPAK-mediated phosphorylation
of CCCs in brain tissues. These results suggest that inhibition of
SPAK kinase is an effective approach in modulating CCCs and
has therapeutic potential for brain disorders of cell volume
dysregulation.
Results
ZT-1a, a novel and potent non-ATP-competitive SPAK inhi-
bitor. To identify pharmacological modulators of SPAK kinase,
we designed and synthesized a new focused chemical library
derived from the previously identified SPAK inhibitors Clo-
santel43, Rafoxanide44, and STOCK1S-1427943 (Fig. 1). This
“scaffold-hybrid” strategy, combining pharmacophores from
different scaffolds, has previously led to development of highly
selective kinase inhibitors45,46. Closantel and Rafoxanide target
the C-terminal domain allosteric sites of SPAK and OSR1, rather
than their highly conserved ATP-binding pockets, leading to non-
ATP-competitive kinase inhibition44. Iterative rounds of medic-
inal chemistry optimization led to identification of 5-chloro-N-(5-
chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)-2-
hydroxybenzamide (“ZT-1a”) as a selective SPAK inhibitor (Fig. 1
and Supplementary Table 1).
We compared the highest-potency salicylic amides selected
from the library with Closantel, STOCK1S-14279, and STOCK1S-
50699 as SPAK inhibitors in a cellular context. As NKCC1 and
KCCs (KCC1–4) are phosphosubstrates of SPAK kinase25,26,
SPAK activity was monitored as NKCC1 Thr203/207/212
phosphorylation, which is required for cotransporter activation36,
and KCC site1/2 phosphorylation (KCC2 Thr906/Thr1007 or
KCC3 Thr991/Thr1048), required for cotransporter
inhibition25,47 (Fig. 2, Supplementary Fig. 1). ZT-1a emerged as
the most potent compound, inhibiting phosphorylation of
NKCC1 p-Thr203/207/212 by 72 ± 5.2% at 1 µM ZT-1a and
phosphorylation of KCC sites 1/2 by 65–77% at 3 µM (both n= 4,
p < 0.01) in HEK-293 cells (Supplementary Table 1). SPAK
phosphorylation at Ser373 was inhibited by 70 ± 3.8% inhibition
at ~3–10 µM ZT-1a (n= 3, p < 0.01; Fig. 2). These results show
ZT-1a to be a more potent modulator of SPAK-dependent CCC
phosphorylation than the current SPAK kinase inhibitors
Closantel, STOCK1S-50699, and STOCK1S-14279.
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We next tested whether ZT-1a mediates kinase inhibition by
competing for ATP binding to kinase in a manner similar to that
of the nonspecific kinase inhibitor staurosporine. As shown in
Supplementary Fig. 3a, staurosporine IC50 values increased
proportionally with increasing ATP concentrations, in contrast
to the unchanged IC50 values of ZT-1a (Supplementary Fig. 3b).
These results suggest that ZT-1a inhibits SPAK kinase in a non-
ATP-competitive manner. The kinase selectivity of ZT-1a was
further assessed using standard radioisotopic enzymatic assays
against a panel of 140 recombinant kinases (Dundee profiling,
Supplementary Table 2)48. ZT-1a exhibits relatively high kinase
selectivity, insofar as 98% of these 140 kinases were not inhibited
by >70% by 1 µM ZT-1a as compared with DMSO control.
Whereas 1 µM ZT-1a did inhibit GSK-3β activity by 60 ± 6%
compared in vitro with DMSO control, GSK-3β Ser9 phosphor-
ylation was not inhibited by 3 µM ZT-1a either in HEK-293 cells
(Supplementary Fig. 4a, b) or in ZT-1a-treated ischemic brain
(Supplementary Fig. 4c, d).
ZT-1a disrupts SPAK interaction with WNK but not with
MO25α. Crystallographic analysis of the human OSR1-conserved
carboxyterminal (CCT) domain complexed to an RFXI motif-
containing peptide derived from WNK49 has shown that the
highly conserved CCT residue Leu473 (mouse SPAK Leu502)
forms critical hydrophobic contacts with the Phe residue of the
RFXI motif. In vitro fluorescence polarization studies confirmed a
0.3-µM binding affinity of the RFXI motif-containing WNK
peptide for purified wild-type SPAK protein, an interaction dis-
rupted by STOCK1S-50699 with IC50 of 2.51 µM (Supplementary
Fig. 5). Neither Closantel nor ZT-1a disrupted binding between
WNK4 and the SPAK CCT domain, suggesting that the ZT-1a
binding site lies outside of the CCT domain (Supplementary
Fig. 5).
In order to establish that ZT-1a binds to SPAK and OSR1 CCT
domains, we employed a SPAK antibody pull-down assay from
HEK-293 cell lysates in the presence of increasing ZT-1a
concentrations, and compared the results with an 18-mer RFQV
peptide from human WNK449 and an 18-mer AFQV negative
control peptide not binding the primary pocket of SPAK and
OSR149. Co-immunoprecipitation of WNK1 with SPAK from
HEK-293 cell lysates was abolished by ZT-1a more potently than
by STOCK1S-50699 or by Closantel, in the absence or presence of
competitor peptide (Supplementary Fig. 6). ZT-1a IC50 values
were not significantly altered by the addition of MO25α, which
activates SPAK/OSR1 ~100-fold and increases SPAK/OSR1-
mediated in vitro phosphorylation of all CCCs25,50 by ~8-fold
(Supplementary Fig. 7).
ZT-1a reduces SPAK-dependent CCC phosphorylation in cells.
To assess CCC phosphorylation changes in response to ZT-1a,
HEK-293 cells were exposed for 30 min either to control isotonic
medium or to hypotonic low [Cl−] medium (to activate SPAK/
OSR1), and then treated with varying concentrations of ZT-1a for
an additional 30 min. ZT-1a, in a dose-dependent manner (1–10
µM), markedly inhibited SPAK/OSR1 phosphorylation at Ser373/
Ser325 (i.e., the activating site phosphorylated by WNK1) and
NKCC1 phosphorylation at Thr203/Thr207/Thr212 (SPAK/
OSR1 target sites whose phosphorylation is required for maximal
transporter activity) in hypotonic low [Cl−] conditions as well as
in control isotonic conditions (Fig. 2). These effects were paral-
leled by similar suppression of KCC3 Thr991/Thr1048 phos-
phorylation, consistent with WNK–SPAK/OSR1-mediated
phosphorylation of these residues25,26.
ZT-1a inhibits NKCC1 but stimulates KCC3 activity. 86Rb+
flux assays have been utilized extensively as a reliable measure-
ment of cation chloride cotransporter activity51–54. Therefore, the
ability of ZT-1a to decrease inhibitory phosphorylation of KCC3
at Thr991/Thr1048 prompted us to assess ZT-1a’s effect on KCC3
activity by measuring hypotonicity-stimulated 86Rb+ uptake in
isotonic or hypotonic low Cl− conditions (Fig. 3a). The fur-
osemide (Furo)-treated cells, either transfected with empty vector
or KCC3 wt cDNA, have significantly decreased K+ flux (p < 0.01;
n= 3). Low KCC3 activity observed in wild-type (WT) HEK-293
cells was consistent with maximal KCC3 phosphorylation at
Thr991/1048 in hypotonic low [Cl−] conditions55. In contrast,
cells expressing KCC3 double mutant Thr991Ala/Thr1048Ala,
mimicking activating dephosphorylation at these sites56, exhib-
ited a >13-fold increase in KCC3 activity compared with WT
KCC3 (p < 0.001; n= 3). ZT-1a activated WT KCC3 activity
>10.6-fold (p < 0.001; n= 3), but failed to increase activity of
KCC3 double mutant Thr991Ala/Thr1048Ala (p > 0.05; n= 3;
Fig. 3a), consistent with ZT-1a antagonism of SPAK-mediated
phosphorylation at these sites.
As expected, given that NKCC1 is maximally phosphorylated
following hypotonic low Cl− conditions, higher NKCC1 activity
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Fig. 2 ZT-1a suppresses CCC phosphorylation. a ZT-1a dose dependently inhibited KCC3 Thr991/Thr1048 phosphorylation in cells. HEK-293 cells were
transfected with a DNA construct encoding wild-type N-terminally FLAG-tagged KCC3. Cells at 36 h post transfection were exposed for 30min to either
control isotonic or hypotonic low [Cl−] conditions, and then treated in the same conditions for an additional 30min in the presence of inhibitors at the
indicated concentrations. Cell lysates were subjected to SDS-PAGE and immunoblot with the indicated antibodies. b Immunoblot quantitation on ZT-1a,
Closantel, STOCK1S-14279, and STOCK1S-50699. Band intensities were quantitated with ImageJ software. ***p < 0.001; **p < 0.01; *p < 0.05; ns,
nonsignificant [by one-way ANOVA with post hoc testing (n= 6, error bars represent the mean ± SEM)].
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was observed. Cells treated with Bumetanide (Bum, an FDA-
approved potent loop diuretic (LD) that acts by antagonizing
NKCC1/NKCC2), whether transfected with empty vector or with
NKCC1 wt cDNA, have significantly decreased K+ flux in
isotonic or in hypotonic low Cl− conditions (p < 0.001; n= 3;
Fig. 3b). In contrast, NKCC1-mediated K+ influx in isotonic or in
hypotonic low Cl− conditions was significantly inhibited by ZT-
1a at concentration > 1 µM (p < 0.01; n= 3; Fig. 3b). These results
demonstrated that ZT-1a stimulates KCC3 activity but inhibits
NKCC1 activity.
ZT-1a inhibits SPAK-dependent CCC phosphorylation in vivo.
To define ZT-1a efficacy in naive mice in vivo, we examined
phosphorylation of SPAK, NKCC1, and NCC in kidney, and
phosphorylation of SPAK, NKCC1, and KCC3 in brain, after
intraperitoneal (i.p.) administration of either ZT-1a (10, 30, 50,
and 100 mg/kg) or Closantel (50 mg/kg as a reference). NCC
phosphorylation (pThr46/50/55/60) and NKCC1 phosphoryla-
tion (pThr203/207/212) were reduced ~83–90 ± 7.9% in naive
WT kidneys 30 min after ZT-1a administration (50 mg/kg; p <
0.01; n= 3; Supplementary Fig. 8b). In contrast, at 60 min after
administration of ZT-1a or Closantel, neither drug had reduced
KCC3 phosphorylation (pThr1048) or NKCC1 phosphorylation
(pThr203/207/212) in naive brains (Supplementary Fig. 8a).
SPAK Leu502 is a residue required for high-affinity recognition of
the RFXV/I motifs in SPAK upstream activator WNK isoforms,
and SPAK502A/502A mice served as controls for true
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Fig. 3 ZT-1a inhibition of SPAK kinase correlates with CCC activity. a 86Rb+ uptake assays in the presence of ZT-1a measure transport activity of KCC3A.
(a—left panel) HEK-293 cells were transfected with constructs encoding the indicated WT or mutant constructs of N-terminally FLAG-tagged KCC3.
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SPAK/OSR1 pathway), and then treated in the same conditions for an additional 30min with 10 µM ZT-1a or 1 mM furosemide (Furo) in the presence of 1
mM ouabain (Na+/K+-ATPase inhibitor) and 0.1 mM bumetanide (NKCC1 inhibitor). 86Rb+ uptake was allowed to proceed for 10 min and was then
quantified by scintillation counting. 86Rb+ uptake counts per minute (CPM)s were normalized per mg protein and plotted for both isotonic and hypotonic
conditions. (a—right panel) HEK-293 cells were transfected with constructs encoding wild-type N-terminally FLAG epitope-tagged KCC3A. Thirty-six
hours post transfection, cells were exposed for 30min to either control isotonic conditions or hypotonic low [Cl−] conditions (to activate the SPAK/OSR1
pathway), and then treated for an additional 30min in the same conditions with the indicated ZT-1a concentrations in the presence of 1 mM ouabain and
0.1 mM bumetanide. Ten-minute 86Rb+ uptake values were quantified by scintillation counting, normalized per mg protein for each condition, and plotted
for both isotonic and hypotonic conditions. ***p < 0.001; **p < 0.01; *p < 0.05; ns—nonsignificant [by one-way ANOVA with post hoc testing (n= 6, error
bars represent the mean ± SEM)]. b 86Rb+ uptake assays in the presence of ZT-1a measure transport activity of NKCC1. (b—left panel) HEK-293 cells were
transfected with WT NKCC1 cDNA construct. Thirty-six hours post transfection, cells were exposed for 30min to either control isotonic conditions or
hypotonic low [Cl−] conditions (to activate the SPAK/OSR1 pathway), and then treated in the same conditions for an additional 30min with 10 µM ZT-1a
or 0.1 mM bumetanide (Bum) in the presence of 1 mM ouabain (Na+/K+-ATPase inhibitor). 86Rb+ uptake was allowed to proceed for 10 min and was then
quantified by scintillation counting. 86Rb+ uptake CPMs were normalized per mg protein and plotted for both isotonic and hypotonic conditions. (b—right
panel) HEK-293 cells were transfected with WT NKCC1 cDNA construct. Thirty-six hours post transfection, cells were exposed for 30min to either control
isotonic conditions or hypotonic low [Cl−] conditions (to activate the SPAK/OSR1 pathway), and then treated for an additional 30min in the same
conditions with the indicated ZT-1a concentrations in the presence of 1 mM ouabain. Ten-minute 86Rb+ uptake values were quantified by scintillation
counting, normalized per mg protein for each condition, and plotted for both isotonic and hypotonic conditions. ***p < 0.001; **p < 0.01; *p < 0.05; ns—
nonsignificant [by one-way ANOVA with post hoc testing (n= 6, error bars represent the mean ± SEM)].
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corresponding residues in SPAK49,57. KCC3 phosphorylation at
pThr1048 was reduced 34 ± 4.6% in brains from SPAK502A/502A
mice (p < 0.01; n= 3; Supplementary Fig. 8a), a model of Gitel-
man syndrome57. Thus, systemically administered ZT-1a has low
efficacy in naive brains, suggesting inefficient ZT-1a transport
across the BBB, likely in part reflecting unfavorable ZT-1a
pharmacokinetics in naive mice (T1/2= 1.8 h, AUC= 2340 h*ng/
mL and %F= 2.2%; Supplementary Table 3).
ZT-1a reduces CSF secretion in hemorrhagic hydrocephalus.
Choroid plexus epithelium (CPe) is the most actively secreting
epithelium in the body38,58, producing up to 500 cc/day of CSF59.
Among all tissues, including kidney57, SPAK kinase is most
highly expressed in CPe3. Several CCCs are also expressed in
choroid plexus60–62, including NKCC1, recently shown to be
essential for CSF secretion1,3. IVH-triggered TLR4 signaling sti-
mulates CSF secretion >3.5-fold and causes hydrocephalus by
increasing functional expression of pSPAK and pNKCC1 in CPe3.
We speculated that intracerebroventricular (ICV) delivery of ZT-
1a into the cerebrospinal fluid might bypass the blood–brain
barrier and allow ZT-1a to exert its effects on SPAK and CCCs
in CPe.
To assess KCC1–4 protein expression in rat choroid plexus, we
first verified isoform specificity of our antibodies. Flag-tagged
KCC1–4 were individually expressed in HEK-293 cells. The
purified fraction of KCC immunoprecipitated by KCC site-2
phospho-antibody was subjected to SDS-PAGE and immunoblot
with each antibody. As evident from Fig. 4a, each antibody
recognized only its respective target, without isoform cross-
reactivity. Although immunospecific, none of these antibodies
were able to detect endogenous KCCs from rat CPe lysates
through direct immunoblot. However, immunoblot of immuno-
precipitated fractions demonstrated robust immunoreaction with
antibodies targeting KCC1, KCC3, and KCC4, whereas CPe
KCC2 abundance remained below the detection limit, consistent
with its documented neuron-specific expression pattern63.
We next tested the effects of ICV delivery of ZT-1a on pSPAK,
pNKCC1, pKCC1, pKCC3, and pKCC4 in rat CPe in the setting
of experimental hemorrhagic hydrocephalus, as described3. ZT-1a
reduced IVH-induced expression of pSPAK by 55 ± 3.6%; p <
0.01; n= 3 and pNKCC1 by 69 ± 4.3%; p < 0.001; n= 3 (Fig. 4b).
ZT-1a reduced post-IVH KCC1 phosphorylation at Thr927/
Thr983 by 12- and 3.4-fold, respectively (p < 0.001; n= 3), KCC3
phosphorylation at Thr991/Thr1048 by 6- and 2.1-fold, respec-
tively (p < 0.001; n= 3), and KCC4 phosphorylation at Thr926/
Thr980 (corresponding to KCC3 Thr991/Thr1048) by ~2-fold (p
< 0.001; n= 3) in CPe (Fig. 4b). Consistent with these results, ZT-
1a treatment for 48 h at 10 µM decreased post-IVH CSF
hypersecretion by ~2.3-fold (p < 0.01), in contrast to the lack of
effect of DMSO vehicle (p > 0.05) (Fig. 4c). These data suggest
that ICV administration of ZT-1a can effectively modulate
pathological CSF secretion by decreasing SPAK–NKCC1/KCC
phosphorylation.
ZT-1a modulates primary cortical neuron volume.
SPAK–NKCC1 signaling plays an important role in regulating
cell volume in response to hypertonic osmotic stress. The effects
of the SPAK inhibitor ZT-1a and the NKCC1 inhibitor bume-
tanide (BMT) on cell volume regulation were assessed in primary
cortical neurons exposed to hyperosmotic stress (370 mOsm/kg
H2O) (Fig. 5a). As shown in Fig. 5b, c, ~30% neurons (16/49 cells)
in control conditions showed regulatory volume increase (RVI) at
a rate of 0.0256 ± 0.006 relative volume change/min in response
to hypertonicity-mediated osmotic shrinkage (p < 0.0001). How-
ever, in the presence of either BMT or ZT-1a, neurons displayed
gradual shrinkage with no RVI response, suggesting roles of
SPAK–NKCC1 complex in counteracting cell shrinkage. Upon
returning to isotonic conditions after hyperosmotic stress, the
drug-treated neurons recovered their volume rapidly (Fig. 5b).
The similar effects mediated by BMT and ZT-1a treatments
suggest that they target the same signaling cascade. The absence
of RVI was also observed in human fibroblast cells treated with
BMT or ZT-1a (Supplementary Fig. 9).
ZT-1a reduces stroke-associated cerebral edema and infarct.
Ischemic stroke is associated with significant upregulation of
SPAK and NKCC1 phosphorylation in peri-infarct cortex, stria-
tum, and corpus callosum39. Genetic inhibition of either SPAK or
NKCC1 decreases ischemic cerebral edema and improves neu-
rological outcomes42,64. We evaluated ZT-1a efficacy in attenu-
ating cerebral infarct and associated cerebral edema in a mouse
model of ischemic stroke39,42. First, we examined intrinsic
immunofluorescence labeling of serum albumin at 24 h after
tMCAO, as an indication of BBB integrity. As shown in Fig. 6a–c,
serum-albumin extravasation into brain parenchyma was ~5-fold
higher in mice with ischemic stroke than in sham-operated mice
(p < 0.05, n= 5–6), suggesting that tMCAO/reperfusion induced
disruption of BBB integrity in ischemic brains. We then assessed
whether ZT-1a penetrates better in ischemic brains due to the
leaky BBB. Two hours after ZT-1a administration (5 mg/kg i.p.),
plasma ZT-1a levels in ischemic and non-ischemic sham mice
were indistinguishable (p= 0.29; n= 10–11, Fig. 6e), whereas ZT-
1a concentration in both CL and IL hemispheres of ischemic
brains was ~1.8-fold higher than that in sham brains (p= 0.006;
n= 10–11, Fig. 6f). Importantly, ZT-1a administration 3 h post
reperfusion decreased infarct volume by ~44% (from 78.1 ±
5.8 mm3 in the vehicle-control group to 43.6 ± 6.5 mm3, p < 0.01,
n= 12, Fig. 7b). Moreover, ZT-1a treatment at either 2.5 or
5 mg/kg reduced cerebral hemispheric swelling by ~36–54% as
compared with vehicle control (p < 0.01, Fig. 7b). Regional cere-
bral blood flow (rCBF) within the 24-h post-stroke period was
unaffected by ZT-1a (Supplementary Fig. 10a–c). These results
confirm that ZT-1a reduces infarct size and ischemic cerebral
edema.
ZT-1a improves neurological function after ischemic stroke.
We evaluated the impact of ZT-1a on progression of sensor-
imotor function deficits in a mouse model of ischemic stroke. The
vehicle-control mice developed persistent, severe neurological
deficits at days 0–7 after stroke, as reflected in elevated neuro-
logical scores of 2.5–2.9 (Fig. 7c). ZT-1a-treated mice exhibited a
progressive decrease in neurological deficit scores between day 1
(2.0 ± 0.2) and day 7 (1.4 ± 0.2, p < 0.01, n= 6). In the corner
test42 evaluating post-ischemic sensory and motor deficits,
vehicle-control mice exhibited behavioral asymmetries 1 day after
stroke, deficits that persisted for 7 days (Fig. 7c). In contrast, ZT-
1a-treated mice showed reduced unidirectional turn preference
and absence of asymmetries by day 7 post stroke. In the adhesive
contact and removal tests that evaluate fine sensorimotor func-
tion deficits65, ZT-1a-treated mice displayed significantly
improved motor function (p < 0.05, n= 6) as compared with
vehicle-control mice. These data show that post-stroke treatment
with ZT-1a significantly improved mouse neurological functional
recovery.
ZT-1a protects gray and white matter after ischemic stroke. We
conducted ex vivo MRI studies of brains from the same cohort of
vehicle-control and ZT-1a-treated mice after completion of their
neurological functional assessment at 7 days post stroke. T2-
weighted MRI analysis further confirmed that ZT-1a treatment
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reduced stroke-induced lesion volume by ~40% and longer-term
brain atrophy (% hemisphere shrinkage) by ~41% (p < 0.05, n=
6, Fig. 7d). To assess the effect of ZT-1a on stroke-induced white
matter injury, we analyzed fractional anisotropy (FA) and
directionally encoded color (DEC) maps of the corpus callosum
(CC) and external capsule (EC) in the vehicle-control and ZT-1a-
treated brains. DEC and FA maps revealed intact CC and EC
tracks in the CL hemisphere (arrows) and injured EC in the IL
hemisphere (arrowheads) (Fig. 7d). FA values were significantly
reduced in the ipsilateral EC tract of the vehicle-control brains,
indicating loss of white matter integrity after stroke. In contrast,
EC tract FA values were undiminished in the IL hemisphere of
ZT-1a-treated mice (p > 0.05, n= 6), and the FA values were
higher than the IL hemisphere in vehicle-control brains (p < 0.05),
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reflecting ZT-1a-mediated preservation of EC white matter
microstructure. These results further suggest that post-stroke
treatment with ZT-1a protects both gray and white matter tissues
in ischemic brains.
ZT-1a inhibits stroke-induced SPAK–CCC phosphorylation.
Ischemia elicits neuronal and glial cell swelling66. In contrast to
the neuron-specific KCC2, NKCC1 and KCC3 are expressed in
both neurons and glia67,68, and play roles in cell volume reg-
ulation69. We therefore examined ZT-1a effects on phosphor-
ylation of SPAK/OSR1, NKCC1, and KCC3 in ischemic mouse
brains. Ischemic stroke increased phosphorylation of pSPAK
(pSer373)/pOSR1 (pSer325) by ~1.5-fold (p < 0.05, n= 6),
pNKCC1 (pThr203/207/212) by ~1.6-fold (p < 0.05, n= 6), and
pKCC3 pThr991 (p < 0.05, n= 6) and pThr1048 by ~1.3-fold
(both p < 0.05) in membrane protein fractions from the ipsi-
lateral (IL) cortical hemisphere at 24 h of reperfusion in vehicle-
control-treated mice, without significant change in the corre-
sponding total protein levels (Fig. 8a, b). Post-stroke adminis-
tration of ZT-1a in mice prevented ischemia-induced increases
of pSPAK/pOSR1, pNKCC1, and pKCC3 (p < 0.05, n= 6)
without alteration in the corresponding total protein expression
Fig. 4 ZT-1a decreases SPAK–CCC phosphorylation in hemorrhagic hydrocephalus. a Representative immunoblots verify antibody specificity. KCC1–4
were expressed in HEK-293 cells. KCC site-2 phospho-antibody pull- down fractions were subjected to SDS-PAGE followed by immunoblot with antibodies
targeting specific transporters (n= 3). b Effect of ZT-1a (ICV, 10mmol) on IVH-induced phosphorylation of SPAK/OSR1, NKCC1, and KCC4 in CPE, as
measured in control rats (CTL) and in rats 48 h post IVH treated with ZT-1a or vehicle (n= 3). CPE lysates were harvested and subjected to
immunoprecipitation (IP) and immunoblot (IB) with the indicated antibodies. D, dimeric KCCs; M, monomeric KCCs. Quantitation of actin-normalized
choroid plexus ion transporter phosphorylation is presented in control rats (CTL) and rats 48 h after experimental IVH in the presence or absence of ZT-1a
or vehicle (n= 3). ***p < 0.001; **p < 0.01; *p < 0.05 versus control rats [by one-way ANOVA with post hoc testing (error bars represent the mean ±
SEM)]. c Effect of SPAK inhibition by 10 µM ZT-1a on IVH-induced CSF hypersecretion by CPE (n= 3). The rate of CSF production (µL/min) is presented as
means ± SEM. ***p < 0.001; **p < 0.01 versus baseline IVH [one-way ANOVA with post hoc testing (error bars represent the mean ± SEM)].
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Fig. 5 Effects of ZT-1a on cell volume changes in mouse primary cortical neurons. a Representative images of calcein-AM-loaded mouse primary cortical
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(Fig. 8a, b; Supplementary Fig. 11). These results indicate that
ZT-1a inhibits the SPAK-dependent upregulation of NKCC1
and KCC3 phosphorylation in ischemic brains.
Closantel reduces ischemic brain injury. We compared the
neuroprotective efficacy of Closantel with that of the pan-WNK-
kinase inhibitor WNK463. Administration of Closantel (1.0 or
2.5 mg/kg) at 3 and at 8 h post reperfusion reduced infarct
volume and hemispheric swelling in a dose-dependent manner (p
< 0.01, n= 5–14, Fig. 9a–c), whereas Closantel at 0.1 mg/kg was
ineffective. As was true for ZT-1a, Closantel did not alter rCBF
(Supplementary Fig. 9a–f). In contrast, WNK463 treatment (2.5
mg/kg) reduced neither infarct volume nor hemispheric swelling
at 24 h post reperfusion (Fig. 9a–c). Moreover, toxicity of Clo-
santel and ZT-1a at 25 mg/kg in naive and ischemic stroke mice
was reflected in Kaplan–Meier survival curves (Supplementary
Fig. 12). Ischemic stroke mice treated with ZT-1a survived longer
than Closantel-treated mice at this high dose (p= 0.008, n= 6,
log-rank test). These data demonstrate that ZT-1a and Closantel
are effective for in vivo inhibition of the WNK–SPAK–CCC
pathway in the mouse model of ischemic brain injury.
Discussion
We have applied a “scaffold-hybrid” strategy to discover and
characterize a potent and selective inhibitor of SPAK kinase,
ZT-1a [5-chloro-N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-
2-methylphenyl)-2-hydroxybenzamide]. About 3 µM ZT-1a
inhibited stimulatory phosphorylation of SPAK Ser373 and
NKCC1 Thr203/Thr207/Thr212, and the inhibitory phosphor-
ylation of the KCCs (e.g., KCC3 Thr991/Thr1048). As shown in
cellular 86Rb+ flux assays, ZT-1a inhibited NKCC1 but potently
stimulated KCC activity >10-fold. In a model of post-hemorrhagic
hydrocephalus, intracerebroventricular delivery of ZT-1a
decreased choroid plexus SPAK–CCC phosphorylation and
antagonized inflammation-induced CSF hypersecretion. In a
model of ischemic stroke, systemic ZT-1a decreased neuronal and
glial CCC phosphorylation, reduced infarct size and cerebral
edema, and improved neurological outcomes. These results sug-
gest that ZT-1a is an effective SPAK–CCC modulator, with
therapeutic potential for treatment of brain disorders associated
with impaired cell volume homeostasis.
The traditional strategy of targeting the ATP-binding site of
SPAK/OSR1 increases risks of off-target kinase inhibition. The
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introduction of STOCK1S-50699 and STOCK2S-2601670 has
highlighted SPAK inhibitors that target the CCT domain rather
than the kinase domain. However, only STOCK1S-50699, but not
STOCK2S-26016, suppressed in vitro phosphorylation of SPAK/
OSR1 and NKCC1 induced by hypotonic low [Cl−]25. Moreover,
in vivo pharmacokinetics of STOCK1S-50699 are unfavorable
(data not shown). The livestock antiparasitic drug, Closantel71,
emerged as the first drug candidate for in vivo pharmacological
inhibition of SPAK43,44, but is contraindicated in humans due to
retinal toxicity72.
The ATP independence of SPAK inhibition by Closantel and
STOCK1S-14279 has suggested the possibility of developing
inhibitors of WNK signaling by binding to constitutively active or
WNK-insensitive (T233E) SPAK43. With a “scaffold-hybrid”
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strategy45,46, we designed and synthesized a new, focused che-
mical library derived from these two ATP-insensitive inhibitors.
ZT-1a was among the best SPAK inhibitors identified from an
~300-compound chemical library, and was characterized by
fluorescence polarization, in vitro kinase, and cell-based assays.
ZT-1a was a more potent CCC inhibitor than its predecessor
SPAK inhibitors, Closantel43, Rafoxanide44, STOCK1S-1427943,
and STOCK1S-5069970. About 3 µM ZT-1a substantially inhib-
ited phosphorylation of SPAK Ser373, NKCC1 Thr203/207/212,
and KCC3 Thr991/Thr1048 (KCC4 Thr926/Thr980) in cells. ZT-
1a also effectively inhibited NKCC1 and stimulated KCC3 in
standard cellular assays of CCC-mediated 86Rb+ flux.
Post-stroke administration of Closantel in mice reduced
ischemic cerebral infarction size and brain swelling in a dose-
dependent manner. However, we detected Closantel toxicity in
mice at higher doses (~25 mg/kg), consistent with reported
adverse effects in humans, including weakness, visual impair-
ment, and blindness72,73. The in vitro nanomolar-potency pan-
WNK-kinase inhibitor WNK463 was developed as an anti-
hypertensive drug74. Oral administration of 1–10 mg/kg
WNK463 reduced blood pressure and regulated body fluid and
electrolyte homeostasis in normotensive and hypertensive rodent
models74. However, 2.5 mg/kg of WNK463 in mice was not
neuroprotective, but elicited ataxia and breathing difficulties, as
previously reported at 1–10 mg/kg doses74. Although the causes
of these adverse effects remain unclear, they also discouraged
efficacy testing of WNK463 at higher doses.
Post-stroke administration of ZT-1a attenuated stroke-
associated infarction and cerebral edema and rapidly improved
neurological function in post-ischemic mice, the results corro-
borated by brain MRI. T2-weighted MRI of ex vivo brains from
ZT-1a-treated mice showed smaller lesion volumes and reduced
brain atrophy at 7 days post stroke. DTI data analysis revealed
that ZT-1a significantly prevented subacute brain white matter
injury after ischemic stroke. ZT-1a thus provides neuroprotec-
tion, at least in part by directly inhibiting SPAK kinase activity
and SPAK-mediated phosphoactivation of NKCC1 and phos-
phoinactivation of KCC3 in ischemic brains. ZT-1a reduced
ischemia-induced elevations of pSPAK and pNKCC1 by 55–65%,
and elevations of pKCC3 by 30% compared with vehicle-control
mice. The ZT-1a-mediated concurrent inhibition of phosphor-
ylation of SPAK and of NKCC1/KCC3 supports our interpreta-
tion that ZT-1a exhibits allosteric inhibition of SPAK kinase
activity likely through binding to the secondary pocket of the
CCT domain, thus preventing SPAK binding and activation by
upstream WNK kinases. A similar dual mechanism of
WNK–SPAK inhibitor STOCK1S-50669 has been reported in
cultured cells44,70.
Plasma half-life of ZT-1a is only ~1.8 h in normal naive mice,
and ZT-1a penetration across the healthy BBB is minimal.
Ischemic stroke injury disrupts BBB tight junctions as early as 30
min after resumption of perfusion75,76, facilitating brain access
for many small-molecule drugs77. We have shown that ischemic
stroke caused robust extravasation of serum albumin into brain
parenchyma, in parallel with detection of elevated ZT-1a levels in
ischemic brain. These findings suggest that ZT-1a more effec-
tively entered ischemic brain parenchyma across a leaky BBB.
However, we cannot rule out possible contributions from altered
BBB drug transporter pathways and/or reduced ZT-1a extrusion
from CNS in the setting of ischemia. Solute carrier (SLC) trans-
porters, such as organic anion-transporting polypeptides (Oatps),
may improve drug delivery into the brain, whereas the ATP-
binding cassette (ABC) transporter superfamily (P-glycoprotein)
exports drugs across BBB endothelial cells into the blood78,79. As
ischemia increases Oatp1a4 protein expression and function in
brain microvessels80, this and other SLC proteins of similar
expression pattern may contribute to increased ZT-1a transport
across BBB into ischemic brains. Whether ZT-1a is a substrate for
Oatp1a4 and ABC superfamily remains to be studied. Ischemic
stroke-induced disruption of the BBB integrity is also evident in
human brains81,82, suggesting that small-molecule neuroprotec-
tive drugs, such as ZT-1a, could potentially traverse the leaky BBB
into ischemic human brain. We administered the initial dose of
ZT-1a 3-h post stroke, a time comparable to the 2.5–4.0-h post-
stroke treatment windows found effective for the candidate
neuroprotective agents, glibenclamide, human albumin, and
minocycline83–85. Although ZT-1a and the antiparasitic drug
Closantel exhibit similar effects in reducing ischemic brain
damage, Closantel shows toxicity in mouse and human72,73. In
this study, we did not test possible visual system toxicity of ZT-1a.
Additional pharmacokinetics and toxicity studies of ZT-1a,
especially on the retina, warrant further investigations for future
clinical translation.
The CPe secretes ~500 ml/day CSF, a higher per-cell fluid
volume than for any other epithelium38. NKCC1 expressed in the
apical CPe contributes approximately half of CSF production,
though its mechanism remains unclear, in view of its unique
apical localization in the CPe compared with its basolateral
position in all other epithelia1. Indeed, some have proposed
inward NKCC1 flux to be required for apical K+ recycling and
continued CSF production86,87, while others have provided evi-
dence for net ion efflux with obligatory water transport directly
contributing to CSF production1,3. Nonetheless, in a rat model of
hemorrhagic hydrocephalus, intraventricular hemorrhage causes
a Toll-like receptor 4 (TLR4)- and NF-κB-dependent inflamma-
tory response in CPe associated with ~3-fold increase in
bumetanide-sensitive CSF secretion3. IVH-induced hypersecre-
tion of CSF is mediated by TLR4-dependent activation of SPAK,
which binds, phosphorylates, and stimulates NKCC1 at the CPe
apical membrane3. Genetic depletion of TLR4 or SPAK nor-
malizes hyperactive CSF secretion rates and reduces post-
hemorrhagic hydrocephalus symptoms in parallel with reduc-
tion of NKCC1 phosphorylation. We have shown here that ICV
administration of ZT-1a restores CSF secretion rates to basal
Fig. 7 ZT-1a decreases brain injury after ischemic stroke. a Experimental design of ischemic stroke study. Vehicle or ZT-1a is administered at 3 and 8 h
post tMCAO. b Representative images and quantitation of infarct volume and hemispheric swelling in TTC-stained coronal sections of mouse brains 24 h
post tMCAO. Vehicle (DMSO, 2ml/kg) or ZT-1a (2.5 or 5.0 mg/kg) were administered via intraperitoneal injection (i.p.) with initial half-dose at 3 h and
second half-dose at 8 h post reperfusion. Data are mean ± SEM, male mice, n= 12 (vehicle), 6 (ZT-1a 2.5), and 12 (ZT-1a 5.0). ***p < 0.001; **p < 0.01
versus vehicle-control mice, one-way ANOVA. c Neurological deficit scores, corner tests, and adhesive tape removal tests of mice 1 day before tMCAO
(–1) and at days 0, 1, 3, 5, and 7 post tMCAO. Vehicle (DMSO, 2ml/kg) or ZT-1a (5.0 mg/kg) were administered as described in b. Data are means ± SEM,
n= 7 for each group (male 4, female 3). ***p < 0.001; **p < 0.01; *p < 0.05 versus the respective vehicle control. d Representative images of T2WI,
directionally encoded color (DEC), and fractional anisotropy (FA) maps of ex vivo brains from the same cohort of mice at 7 days post tMCAO, as described
in c. Arrow marks EC (external capsule); double arrowhead marks damaged EC; CC: corpus callosum. Bar graphs display quantitation of brain lesion
volume, brain atrophy (% shrinkage), and mean FA values. Data are means ± SEM, n= 6 for vehicle (male 3, female 3) and 7 for ZT-1a (male 4, female 3).
*p < 0.05, one-way ANOVA.
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Fig. 8 ZT-1a decreases ischemia-induced SPAK–CCC phosphorylation. a Representative immunoblots (IB) of phospho-SPAK/OSR1 (pSPAK/pOSR1),
phospho-KCC3 (pKCC3), and phospho-NKCC1 (pNKCC1) in mouse brains studied 24 h post reperfusion after ischemic stroke. Membrane protein fractions
were prepared from contralateral (CL) and ipsilateral (IL) cerebral hemispheres. Vehicle (Veh, DMSO) or ZT-1a (5mg/kg) were administered as described
in Fig. 7a. Na+–K+ ATPase α-subunit served as loading control for membrane protein fraction. b Densitometry analyses of immunoblots (similar to those in
panel a) of pSPAK/pOSR1, pKCC3, pNKCC1, tSPAK/tOSR1, and tNKCC1 in mouse brains studied 24 h of reperfusion after tMCAO. Data are means ± SEM,
n= 6 per group (male 3, female 3). ***p < 0.001; **p < 0.01; *p < 0.05 versus control, one-way ANOVA.
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levels after IVH, and antagonizes IVH-induced phosphorylation
of SPAK, NKCC1, and multiple KCCs in CPe. These data cor-
roborate previous findings1,3, and suggest ZT-1a or related stra-
tegies as potential nonsurgical treatment modalities for
hydrocephalus. Further work will be required to determine the
mechanisms of NKCC1 ion transport at the CPe membrane, and
to assess the therapeutic potential of ZT-1a in other preclinical
models of hydrocephalus.
In conclusion, we have developed ZT-1a, a novel drug that
potently and selectively inhibits SPAK kinase, the master reg-
ulator of CCCs. ZT-1a inhibits NKCC1 and stimulates the KCCs
by decreasing their regulatory phosphorylation. Intracer-
ebroventricular delivery of ZT-1a, by decreasing inflammation-
induced phosphorylation of CCCs in the choroid plexus, reduces
CSF hypersecretion in hemorrhagic hydrocephalus. Systemically
administered ZT-1a attenuates cerebral edema, protects against
ischemic brain damage, and improves post-ischemic neurological
outcomes by reducing ischemia-induced CCC phosphorylation.
These results suggest that ZT-1a or related compounds are
effective CCC modulators, with therapeutic potential for treat-
ment of disorders of dysregulated brain volume homeostasis.
Methods
Reagents and general methods. Protein sample buffer and bicinchoninic acid
assay reagent were from Thermo Scientific (Rockford, IL). Closantel was from
Sigma (St. Louis, MO) and WNK463 was from MedChemExpress (Princeton, NJ).
STOCK1S-50699 and STOCK1S-14279 were from InterBioScreen (Chernogolovka,
Russian Federation). Horseradish peroxidase (HRP)-conjugated anti-rabbit Ig was
from Molecular Probes (Eugene, OR). RIPA buffer and enhanced chemilumines-
cence agent (ECL) reagent were from Pierce (Rockford, IL).
Antibodies. The Division of Signal Transduction Therapy Unit at the University of
Dundee (RRID:SCR_011633) supplied antibodies to KCC3 (1 µg/ml, S701C),
KCC3A phosphoT991 (1 µg/ml, S959C), KCC3A phosphoT1048 (1 µg/ml, S961C),
NKCC1 (1 µg/ml, S022D), NKCC1 phospho-T203/T207/T212 (1 µg/ml, S763B),
WNK1 (1 µg/ml, S079B), SPAK (1 µg/ml, S551D), OSR1 (1 µg/ml, S850C), SPAK/
OSR1 (S-motif) phosphoS373/S325 (1 µg/ml, S670B), and full-length human ERK1
(1 µg/ml, S221B). The pan-KCC2 antibody (NeuroMab clone N1/12) was from
NeuroMab. The FLAG M2 antibody (1 µg/ml, F3165) was from Sigma. The KCC4
antibody was from Novus Biologicals (0.4 µg/ml, NBP1-85133). Antibodies to
GSK-3β phosphoS9 (1:1000 dilution, #9336), GAPDH (0.1 µg/ml, #2118), and
β-Actin (1:5000 dilution, 8H10D10) were from Cell Signaling Technology. Anti-
pGSK-3α/β (1:1000 dilution, #OPA1-03083) was from Thermo Scientific. Anti-Na
+–K+–ATPase alpha subunit (1:1000 dilution, #a5c) was from the Developmental
Studies Hybridoma Bank (RRID:SCR_013527, Iowa City, IA). Horseradish
peroxidase-coupled secondary antibodies for immunoblotting were from Pierce.
IgG used in control immunoprecipitation experiments was affinity-purified from
pre-immune sera using Protein-G-Sepharose.
Cell culture, transfections, and stimulations. HEK-293 (human embryonic
kidney 293) cells were cultured on 10-cm-diameter dishes in DMEM supplemented
with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and
0.1 mg/ml streptomycin. HEK-293 cells were transfected with a mixture of 20 μl of
1 mg/ml polyethylenimine (Polysciences) and 5–10 μg of plasmid DNA as descri-
bed previously26. Thirty-six hours post transfection, cells were stimulated with
either control isotonic or hypotonic medium for a period of 30 min. Cells were
lysed in 0.3 ml of ice-cold lysis buffer/dish, lysates were clarified by centrifugation
at 4 °C for 15 min at 26,000 g, and the supernatant aliquots were frozen in liquid
nitrogen and stored at –20 °C. Protein concentrations were determined using the
Bradford method. Cells were treated with the indicated concentrations of the
SPAK/OSR1 inhibitors. Isotonic buffer was 135 mM NaCl, 5 mM KCl, 0.5 mM
CaCl2, 0.5 mM MgCl2, 0.5 mM Na2HPO4, 0.5 mM Na2SO4, and 15 mM HEPES
(pH 7.5). Hypotonic low-chloride buffer was 67.5 mM sodium gluconate, 2.5 mM
potassium gluconate, 0.25 mM CaCl2, 0.25 mM MgCl2, 0.5 mM Na2HPO4, 0.5 mM
Na2SO4, and 7.5 mM HEPES (pH 7.5).
Primary mouse neuronal cultures. Embryonic day 14–18 wild-type pregnant
mice, in a C57BL6J background, were deeply anesthetized with 5% isoflurane and
euthanized by cervical dislocation39. Fetuses were removed from the uterus and the
brain cortical tissues were dissected in ice-cold Hank’s balanced salt solution. The
cortical tissues were exposed to 0.125 mg/mL of trypsin at 37 °C for 20 min.
The dissociated cells were centrifuged at 587 × g for 5 min at room temperature.
The cells were gently mixed into a single-cell suspension before plating. Cells
(200–1000 cells/mm2) were cultured on glass coverslips coated with poly-D-lysine
in neurobasal medium containing B-27 supplements, L-glutamine, and penicillin/
streptomycin (100 U/mL and 0.1 mg/mL, respectively). Cultures were incubated at
37 °C in an incubator with 5% CO2 and atmospheric air. Neurons in culture for
7–9 days were used in the study.
Human fibroblasts. Primary fibroblast cell culture was established as described88.
Passaged cells (2 × 105 cells per coverslip) were cultured on glass coverslips coated
with poly-D-lysine in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 0.1 mg/mL penicillin/streptomycin. Cul-
tures were incubated at 37 °C in an incubator with 5% CO2 and atmospheric air.
Passages 9–21 were used in the study.
86Rb+ uptake assay for KCC3 or NKCC1 activity. 86Rb+ uptake assays were
performed on HEK-293 cells transfected with WT or mutant KCC3 plasmid DNAs
as detailed in several of our previous publications25,26. For measurement of NKCC1
activity, HEK-293 cells were transiently transfected with empty vector or wt
NKCC1 plasmid DNA. HEK-293 cells were plated at 50–60% confluence in 12-well
plates (2.4-cm-diameter wells) and transfected with wild-type or various mutant
forms of full-length flag-tagged human KCC3 (1 μg of plasmid DNA per well) in
the presence of 2.5 μl of polyethylenimine (1 mg/ml). The 86Rb+-uptake assay was
performed on cells at 36 h post transfection. Culture medium was aspirated from
the wells and replaced with either isotonic or hypotonic medium for 15 min at 37 °
C, and then for a further 15 min with stimulating medium containing additional
1 mM ouabain (Oua, Na+/K+–ATPase inhibitor) and 0.1 mM bumetanide (Bum,
inhibitor of NKCC1 cotransporter). For measurement of NKCC1 activity in HEK-
293 cells, stimulating medium contained ouabain, and with or without further
addition of bumetanide as for controls. This stimulating medium was then
removed and replaced with isotonic medium containing inhibitors plus 2 µCi/ml
86Rb+. After incubation for 10 min at 37 °C, cells were rapidly washed three times
with the respective ice-cold nonradioactive medium. Washed cells were lysed in
300 µl of ice-cold lysis buffer and 86Rb+ uptake was quantitated by liquid scintil-
lation counting (PerkinElmer).
Cell volume measurements. Cell volume change was determined using Calcein-
AM as a marker of intracellular water volume89. The coverslip-plated cells were
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Fig. 9 The SPAK inhibitor Closantel exhibits dose-dependent
neuroprotective effects. a Representative images of TTC-stained coronal
sections of mouse brain 24 h post tMCAO. Vehicle (Veh) control (DMSO,
2ml/kg), Closantel (0.1, 1.0, or 2.5mg/kg), or WNK463 (2.5mg/kg body
weight) were administered i.p. in divided doses at 3 and 8 h post reperfusion
after tMCAO. b, c Quantitative analysis of mean infarct volume and mean %
hemispheric swelling of mouse brains 24 h post tMCAO. Data are means ±
SEM, male mice, n= 14 (vehicle), 8 (Closantel 0.1), 8 (Closantel 1.0),
5 (Closantel 2.5), and 4 (WNK463 2.5). ***p < 0.001 and **p < 0.01 versus
vehicle control, one-way ANOVA.
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incubated with 0.5 µM calcein-AM for 30 min at 37 °C in the dark. The coverslip
was then mounted in a heated (37 °C) imaging/perfusion chamber (Warner
Instruments, Hamden, CT) on a Nikon Ti Eclipse inverted epifluorescence
microscope equipped with 40× Super Fluor oil immersion objective, and a Prin-
ceton Instruments MicroMax CCD camera. Calcein fluorescence was monitored
using a FITC filter set (excitation 480 nm, emission 535 nm, Chroma Technology,
Rockingham, VT). Images were collected every 60 s with MetaFluor image-
acquisition software (Molecular Devices, Sunnyvale, CA) and regions of interest
(~20–25 cells) were selected. Baseline drift resulting from photobleaching and dye
leakage was corrected as described before90. Fluorescence change was plotted as a
function of the reciprocal of the relative osmotic pressure and the resulting cali-
bration curve applied to all subsequent experiments as described before90. The
HEPES-buffered isotonic solution contained (in mM, pH 7.4) 100 NaCl, 5.4 KCl,
1.3 CaCl2, 0.8 MgSO4, 20 HEPES, 5.5 glucose, 0.4 NaHCO3, and 70 sucrose with
osmometer-confirmed osmolarity of 310 mOsm (Advanced Instruments, Nor-
wood, MA). Anisosmotic solutions (250, 370, 400, and 515 mOsm) were prepared
by removal or addition of sucrose to the above solution.
Immunoblot and phospho-antibody immunoprecipitation. Whole-cell or cere-
brospinal fluid (CSF) lysates were prepared with RIPA lysis buffer as previously
described3,91. Lysate protein samples were subjected to immunoblot and immu-
noprecipitation as previously described25. Protein samples (40 µg) were boiled in
sample buffer for 5 min, resolved by 7.5% sodium dodecyl sulfate polyacrylamide-
gel electrophoresis, and electrotransferred onto a polyvinylidene difluoride
membrane25,92,93. Membranes were incubated for 30 min with TBST (Tris-buffered
saline, 0.05% Tween-20) containing 5% (w/v) skim milk. Blots were then washed
six times with TBST and incubated for 1 h at room temperature with secondary
HRP-conjugated antibodies diluted 5000-fold in 5% (w/v) skim milk in TBST.
After repeating the washing steps, signals were detected with enhanced chemilu-
minescence reagent. Antibodies used in Supplementary Fig. 11 (anti-phospho-
NKCC1, pNKCC1), anti-pSPAK/pOSR1, and antibody to total SPAK/OSR1
(tSPAK/tOSR1) were the kind gifts of Dr. Yang (Taiwan National University)94.
Immunoblots were developed using a film automatic processor (SRX-101, Konica
Minolta Medical) and films were scanned at 600 dpi (PowerLook 1000, UMAX).
Figures were generated using Photoshop/Illustrator (Adobe). Band densities were
measured with ImageJ. For phospho-antibody immunoprecipitation, KCC iso-
forms were immunoprecipitated from indicated cell extracts. Two mg of the
indicated clarified cell extract was mixed with 15 µg of the indicated phospho-
specific KCC antibody conjugated to 15 μl of protein-G-Sepharose, in the added
presence of 20 μg of the dephosphorylated form of the phosphopeptide antigen,
and incubated for 2 h at 4 °C with gentle shaking. Immunoprecipitates were washed
three times with 1 ml of lysis buffer containing 0.15M NaCl and twice with 1 ml of
buffer A. Bound proteins were eluted with 1× LDS sample buffer.
Model of post-hemorrhagic hydrocephalus. All animal experiments were
approved by the Institutional Animal Care and Use Committee (IACUC) of the
Yale University, and in accordance with the guidelines and regulations in the NIH
Guide for the Care and Use of Laboratory Animals. Male Wistar rats (Harlan,
Indianapolis, IN, USA), age 8 weeks (220–230 g), were anesthetized (60 mg/kg
ketamine plus 7.5 mg/kg xylazine, IP) and allowed to breathe room air sponta-
neously. Body temperature was maintained at 37 ± 1 °C (Harvard Apparatus,
Holliston, MA, USA) throughout the course of the experiments. PHH was modeled
using a modified protocol based on previously described methods91,95. Briefly, the
tail artery of an anesthetized rat was aseptically cannulated using a flexible catheter
(PE-20) preloaded with heparinized saline. The rat was then mounted in a ste-
reotactic apparatus (Stoelting Co., Wood Dale, IL), a midline scalp incision was
made to expose the skull, and a 1-mm burr hole was made using a high-speed drill
over the right lateral ventricle (coordinates, x=−0.8, y=−1.7 mm relative to
bregma). Approximately 200 µL of blood was drawn from the tail artery catheter
and loaded into a 500-µL syringe (Hamilton, Reno, NV), which was mounted to
the stereotactic frame. Under stereotactic guidance, 50 µL of freshly collected
autologous blood, free from anticoagulants, was infused into the right lateral
ventricle (coordinates, x=−0.8, y=−1.7, and z=−4.5 mm relative to bregma),
over the course of 5 min, and the 26-gauge needle was held in place for an addi-
tional 20 min to prevent backflow of blood upon needle removal.
Quantitation of rates of CSF production and intracerebroventricular drug
administration. Rates of CSF production were measured as previously described91.
Briefly, anesthetized rats were mounted in a stereotactic apparatus and a 1.3-mm
burr hole was made over the left lateral ventricle (coordinates, x= –0.8, y=+1.7
relative to bregma). Over the right lateral ventricle, an Alzet brain infusion cannula
(#1; Durect, Cupertino, CA) was mounted with one spacer to adjust to –4.5-mm
depth. The cannula was then connected to a 1-mL syringe loaded with either ZT-1a
or vehicle solution (see below) via PE-20 catheter tubing to a syringe infusion
apparatus (Pump elite 11, Harvard Apparatus). Next, the rat’s head was rotated on
the ear bars 90°, nose down, and the suboccipital muscles were dissected to the
cisterna magna to expose the atlanto-occipital ligament. The ligament was punc-
tured and a 23-gauge flexible catheter (PE-20) was advanced 5 mm through the
foramen of Magendie to the 4th ventricle. Sterile, molecular-grade mineral oil
(100 µL, Sigma Aldrich, St. Louis, MO) was infused into the 4th ventricle to occlude
the aqueduct of Sylvius, thereby creating a closed system of CSF circulation. With
the rat in the same position, a glass capillary tube (cat # CV8010-300, borosilicate,
OD, 1 mm; ID, 0.8 mm; length, 30 cm; VitroCom, Mountain Lakes, NJ) was
advanced through the burr hole into the left lateral ventricle. The total volume (V)
of CSF at a given time point was calculated as V(mm3)= π · r2 · d, where r is the
radius of the capillary tube and d is the distance that CSF traveled within the
capillary. The rate of CSF formation (µL/min) was calculated from the slope of the
volume–time relationship. A baseline rate of spontaneous CSF secretion (no drug
infusion) was calculated over 30 min prior to drug infusion, and then compared
with the calculated rate of CSF formation following 30 min of ZT-1a infusion.
ZT-1a solution preparation. Intraventricular infusion solutions were made
using sterile artificial cerebrospinal fluid (aCSF), composed of (in mM) sodium,
150; potassium, 3.0; calcium, 1.4; magnesium, 0.8; phosphorus, 1.0; chloride, 155,
pH 7.19 (Tocris, Bristol, UK), with a calculated osmolarity of 311.2 mOsmC/l3,91.
ZT-1a was dissolved in aCSF using DMSO as a co-solvent and titrated to pH 9
(10 mmol, 1% DMSO, pH 9). As a control, a vehicle solution of aCSF (1% DMSO,
pH 9) omitting ZT-1a was prepared and tested.
Tissue harvest and choroid plexus isolation. Rats were euthanized via overdose
of pentobarbital (Euthasol) administered IP and transcardially perfused with ice-
cold normal saline. The brain was rapidly isolated and then placed in an ice-cold
saline bath, after which the choroid plexus was carefully dissected under magni-
fication using sharp forceps. Approximately 3 mg of choroid plexus tissue was
harvested from each brain, collected into a 1.5-mL tube, and flash frozen in liquid
nitrogen for storage.
Middle cerebral artery occlusion model. Focal cerebral ischemia was induced by
transient occlusion of the left middle cerebral artery (MCA) for 50 min42,92. Under
an operating microscope, the left common carotid artery was exposed through a
midline incision. Two branches of the external carotid artery (ECA), occipital and
superior thyroid arteries, were isolated and coagulated. The ECA was dissected
further distally and permanently ligated. The internal carotid artery (ICA) was
isolated and carefully separated from the adjacent vagus nerve. A 12-mm length of
silicon-coated nylon filament (size 6-0, native diameter 0.11 mm; diameter with
coating 0.21 ± 0.02 mm; coating length 5–6 mm; Doccol Corporation, Sharon, MA)
was introduced into the ECA lumen through a puncture. The silk suture around
the ECA stump was tightened around the intraluminal nylon suture to prevent
bleeding. The nylon suture was then gently advanced from the ECA to the ICA
lumen until mild resistance was felt (~9 mm). For reperfusion, the suture was
withdrawn 50 min after MCAO to restore blood flow. Body temperature was
maintained for the duration of the experiment between 36.5 °C and 37 °C with a
small-animal heating pad (Kent Scientific).
Preparation of brain membrane and cytosolic protein fractions and immu-
noblotting. Brain homogenates were prepared at 24 h post reperfusion92. Mice
were anesthetized with 5% isoflurane vaporized in N2O and O2 (3:2), then
decapitated. The contralateral (CL) and ipsilateral (IL) brain tissues were dissected
in five volumes of cold homogenization buffer (0.25 M sucrose, 10 mM Tris-HCl,
1 mM EDTA, pH 7.4, protease, and phosphatase inhibitor cocktail, Pierce). Brain
tissues were gently homogenized with a tissue grinder (Kontes, Vineland, NJ, USA)
for 10 strokes in homogenization buffer. The homogenized samples were cen-
trifuged at 1000 × g at 4 °C for 10 min. The supernatant (S1) was collected and
centrifuged at ~200,000 × g for 30 min in a Beckman OptimaTM XL-80k Ultra-
centrifuge. The cytosolic fraction [supernatant (S2)] and crude membrane pellet
were collected. The pellet was resuspended in the homogenization buffer. Protein
content in both membrane and cytosolic fractions was determined by the standard
bicinchoninic acid method.
Kinome profiling. Kinome profiling was performed using KinomeScan ScanMAX
at 1 μM compound concentrations (see Supplemental Data). Protocols are available
from DiscoverX (https://www.discoverx.com/).
Animal preparation. All animal experiments were approved by the University of
Pittsburgh Institutional Animal Care and Use Committee and performed in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Nine- to 14-week-old C57BL/6 J mice (both male and female)
were used in the study (Jackson laboratories, Bar Harbor, ME).
Drug treatment. Vehicle 100% DMSO (2 ml/kg body weight/day), WNK463
(2.5 mg/kg body weight/day), Closantel (0.1–2.5 mg/kg body weight/day,) or ZT-1a
(2.5–5.0 mg/kg body weight/day) were administered via intraperitoneal injection
(i.p., Fig. 7a), with an initial half-dose at 3 h and the second half-dose at 8 h
following reperfusion.
Cerebral blood flow measurement. Regional cerebral blood flow was measured
using a two-dimensional laser speckle contrast analysis system (PeriCam PSI
High Resolution with PIMSoft, Perimed)65. Isoflurane-anesthetized mice were
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head-fixed using stereotaxic equipment during imaging. The skin was retracted to
expose the intact skull. Images were taken at 19 frames/second with averaging.
Average signal intensity was taken from fixed-size (0.5-mm2) regions of interest
drawn over the parietal bone plate on the ipsi (IL)- and contralateral (CL) sides.
Percent perfusion values were taken in comparison with the mean values of the
pre-ischemic ipsilateral side. Five consecutive images at each time period per
animal were averaged for analysis.
Brain infarction volume and hemispheric swelling measurements. At 24 h of
reperfusion, mice were anesthetized with 5% isoflurane and then decapitated.
Coronal brain tissue slices (2 mm) were stained for 20 min at 37 °C with 1% 2,3,5-
triphenyltetrazolium chloride monohydrate (TTC, Sigma, St. Louis, MO) in PBS
solution. Infarction volume was calculated with correction for edema using ImageJ
software as described96. The extent of hemispheric swelling was calculated using
the following equation: swelling (% contralateral side)= [(volume of ipsilateral
hemisphere − volume of contralateral hemisphere)/volume of contralateral
hemisphere] × 10092.
Neurological deficit score. A neurological deficit grading system42,92 was used to
evaluate neurological deficit at 0, 1, 3, 5, and 7 days after tMCAO. The scores are 0,
no observable deficit; 1, forelimb flexion; 2, forelimb flexion and decreased resis-
tance to lateral push; 3, forelimb flexion, decreased resistance to lateral push, and
unilateral circling; 4, forelimb flexion and partial or complete lack of ambulation.
Corner test. Corner test was used to assess MCAO-induced sensorimotor
abnormalities as described previously42. In brief, the corner test apparatus consists
of two cardboards (30 × 20 × 1 cm each) placed together at a 30° angle to form a
narrow alley. The mouse was placed between the two angled boards facing the
corner. When exiting the corner, uninjured mice turned left or right randomly.
After tMCAO, animals with unilateral brain damage displayed an asymmetry in
corner turning. The numbers of left and right turns of each mouse during 10 trials
were recorded, and turning movements that were not part of a rearing movement
were not scored. Preoperative training was carried out twice per day for 3 days
prior to operation. Postoperatively, animals were tested on days 1, 3, 5, and 7.
Adhesive-removal test. An adhesive-removal test was used to measure somato-
sensory deficits as described previously42,65. In brief, two small pieces of adhesive
tape (4 × 3 mm) were attached to the forepaws in an alternating sequence and with
equal pressure by the experimenter before each trial. Animals were released into a
testing cage, and the time of contact and removal of the adhesive patch were
recorded. Contact was recorded when either shaking of the paw or mouth contact
occurred. The trial ended after the adhesive patch was removed or after 2 min had
elapsed. Preoperative training was carried out twice per day for 3 days prior to
operation. Postoperatively, animals were tested on days 1, 3, 5, and 7.
DTI ex vivo brains. Seven days post reperfusion, mice were anesthetized with 5%
isoflurane, transcardially perfused with 4% paraformaldehyde (PFA), and decapi-
tated42. For ex vivo MRI, brains were maintained within the skull to avoid ana-
tomical deformation. After overnight postfixation in 4% PFA, heads were stored in
PBS solution at 4 °C. MRI was performed at 500MHz using a Bruker AV3HD
11.7 T/89-mm vertical-bore small-animal MRI scanner, equipped with a 25-mm
quadrature RF coil and Paravision 6.0 (Bruker Biospin, Billerica, MA). Following
positioning and pilot scans, a DTI data set covering the entire brain was collected
using a multislice spin echo sequence with 3 reference and 30 noncollinear
diffusion-weighted images with the following parameters: TE/TR= 22/5000 ms,
4 averages, matrix size= 192 × 192 reconstructed to 256 × 256, field of view=
17.3 × 17.3 mm, 33 axial slices, slice thickness= 0.5 mm, b value= 1200 s/mm2,
and Δ/δ= 10/5 ms.
DTI data were analyzed with DSI Studio (http://dsistudio.labsolver.org/)42. In a
blinded manner, region of interests (ROIs) were manually drawn for the ipsilateral
(IL) and contralateral (CL) cortex, striatum, corpus callosum (CC), and external
capsule (EC). Values for the fractional anisotropy (FA), afferent diffusion
coefficient (ADC), and diffusivity were calculated for the entire volume of each
ROI. For atrophy assessment during the subacute phase (7 days post stroke),
percentage hemispheric shrinkage (% shrinkage) was determined by the difference
in volume between two hemispheres and then divided by the CL hemispheric
volume according to the formula: % Shrinkage= (CL volume – IL volume)/CL
volume × 100, as described97,98.
Statistical analysis. Animal subjects were randomly assigned into different studies
and surgical procedures, and investigators blinded to experimental conditions
performed data analyses. The number of animals studied was 80% powered to
detect 20% changes with α (2-sided)= 0.05. A total of 168 mice were used in the
study, and no results were excluded from the analysis. Data were expressed as
means ± SEM. Statistical significance was determined by student’s t test, or one-
way or two-way ANOVA using the Tukey’s post hoc test in the case of multiple
comparisons (GraphPad Prism 7.0, San Diego, CA, USA). Neurological deficit
scores were analyzed by the nonparametric Mann–Whitney test. A probability
value < 0.05 was considered statistically significant. Detailed methods are available
in the Supplementary Informaiton.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. The source data underlying Figs. 2b, 3a, b, 4b, c, 5c, 6c,
e, f, 7b–d, 8b, and 9b, c and Supplementary Figs. 2, 3, 4b, d, 5–8, 9c, 10b, c, e, f, 11b, c,
and 12 are provided as a Source Data file.
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